Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Bupropion for Loss-of-Control Eating After Bariatric Surgery
NCT04605081Phase 3Completed
- Sponsor
- Yale University
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Naltrexone+Bupropion Medication with Placebo (2 arms). Primary endpoints: Loss-of-control Eating Relapse at 12 months and Percent Weight Change at 12 months. Started Jun 2022; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04605081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605081.